3M Company
MMMNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $189.37 Prior regular-session close from the quote source.
- $187.83–$190.32 Regular-session low and high so far today.
- 2.2M Regular-session shares traded · Nov 11, 4:01 PM ET.
- Jan 19 projected Projected for 2027-01-19 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $139.34–$196.90 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own MMM if 3M's durable value comes from a diversified portfolio of patented industrial, safety and healthcare products that generate predictable revenue near $25B and mid-to-high-teens operating margins — but the stock's upside hinges on shrinking legacy.
MMM price history
Loading recent earnings…
Investment thesis
What must happen next
Core end-market demand and product breadth keep reported revenue around the mid-$20B range absent a major industrial downturn or large divestiture, so organic top-line decline would signal a structural market share loss.StrengtheningMateriality: High
Revenue was $24.61B in FY2023, $24.575B in FY2024 and $24.948B in FY2025 — showing stability at ~ $24–25B. If revenue stays near $24–25B, 3M can focus on margin expansion and liability resolution; if revenue falls materially, the company may lack the cash to both settle liabilities and fund returns.
Watch: A prolonged global industrial downturn (weak industrial capex or safety spending) that reduces demand across multiple product lines.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Revenue was $24.61B in FY2023, $24.575B in FY2024 and $24.948B in FY2025 — showing stability at ~ $24–25B.
Open source ↗3M's combination of proprietary materials, scale manufacturing and branded products allows it to sustain mid-to-high-teens operating margins in normal years; margin collapses will primarily come from one-time litigation or regulatory charges rather than competitive price erosion.HoldingMateriality: High
Operating income of $4.629B in FY2025 (~18.6% of revenue) and $4.822B in FY2024 (~19.6%), after a one-time operating loss of -$10.689B in FY2023. Sustained healthy operating margins are necessary to convert revenue into cash to pay down liabilities and fund shareholder returns; if margins are repeatedly hit by structural pricing pressure, valuation deteriorates even if revenue holds.
Watch: Recurring regulatory fines, product bans (for example on chemical product lines) or adverse court rulings that require large operating charges again.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating income of $4.629B in FY2025 (~18.6% of revenue) and $4.822B in FY2024 (~19.6%), after a one-time operating loss of.
Open source ↗The principal driver of earnings and equity volatility is legacy litigation/reserve risk — large adverse settlements materially depress operating income, EPS and equity; conversely, materially lower future litigation cost expectations unlock equity value.StrengtheningMateriality: Medium
A severe operating loss (-$10.689B) in FY2023 followed by positive operating income in FY2024 ($4.822B) and FY2025 ($4.629B) implies material one-time/lumpy charges affected results in 2023. If litigation risk recedes, reported earnings and shareholder equity should normalize and enable freer capital returns; if litigation continues or grows, profit volatility and balance-sheet strain persist, capping valuation.
Watch: Adverse multi-district litigation verdicts or regulatory decisions that substantially increase settlement estimates.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
A severe operating loss (-$10.689B) in FY2023 followed by positive operating income in FY2024 ($4.822B) and FY2025 ($4.629B) implies material.
Open source ↗Sustained recovery in operating cash flow is required to fund dividends, buybacks and liability settlements; absent restoration to the pre-2023 cash generation regime, capital returns will be constrained.StrengtheningMateriality: Medium
Operating cash flow fell from $6.68B in FY2023 to $1.819B in FY2024 and rose modestly to $2.306B in FY2025, showing weakened cash conversion versus historical levels. Free cash flow funds shareholder returns and deleveraging; if OCF remains depressed, management must choose between paying settlements, preserving the dividend, or cutting buybacks — all affecting equity returns.
Watch: Large, recurring legal cash outflows or adverse settlement schedules that materially reduce available operational cash.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating cash flow fell from $6.68B in FY2023 to $1.819B in FY2024 and rose modestly to $2.306B in FY2025, showing.
Open source ↗High nominal liabilities and eroded shareholders' equity materially constrain flexibility; meaningful deleveraging or liability reduction is required before aggressive buybacks or larger M&A resumes.HoldingMateriality: Medium
Stockholders' equity dropped from $14.722B in FY2022 to $4.807B in FY2023 and remained low at $3.842B in FY2024 and $4.702B in FY2025 while liabilities stayed elevated (~$32–45B range across years). If liabilities remain high and equity stays low, credit ratings, borrowing costs and management's ability to return capital will be impaired; reducing liabilities restores optionality and supports valuation multiple expansion.
Watch: Additional large settlements or reserve increases that further erode equity.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders' equity dropped from $14.722B in FY2022 to $4.807B in FY2023 and remained low at $3.842B in FY2024 and $4.702B.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Core end-market demand and product breadth keep reported revenue around the mid-$20B range absent a major industrial downturn or large divestiture, so organic top-line decline would signal a structural market share loss. If revenue stays near $24–25B, 3M can focus on margin expansion and liability resolution; if revenue falls materially, the company may lack the cash to both settle liabilities and fund returns.
3M's combination of proprietary materials, scale manufacturing and branded products allows it to sustain mid-to-high-teens operating margins in normal years; margin collapses will primarily come from one-time litigation or regulatory charges rather than competitive price erosion. Sustained healthy operating margins are necessary to convert revenue into cash to pay down liabilities and fund shareholder returns; if margins are repeatedly hit by structural pricing pressure, valuation deteriorates even if revenue holds.
The principal driver of earnings and equity volatility is legacy litigation/reserve risk — large adverse settlements materially depress operating income, EPS and equity; conversely, materially lower future litigation cost expectations unlock equity value. If litigation risk recedes, reported earnings and shareholder equity should normalize and enable freer capital returns; if litigation continues or grows, profit volatility and balance-sheet strain persist, capping valuation.
Sustained recovery in operating cash flow is required to fund dividends, buybacks and liability settlements; absent restoration to the pre-2023 cash generation regime, capital returns will be constrained. Free cash flow funds shareholder returns and deleveraging; if OCF remains depressed, management must choose between paying settlements, preserving the dividend, or cutting buybacks — all affecting equity returns.
High nominal liabilities and eroded shareholders' equity materially constrain flexibility; meaningful deleveraging or liability reduction is required before aggressive buybacks or larger M&A resumes. If liabilities remain high and equity stays low, credit ratings, borrowing costs and management's ability to return capital will be impaired; reducing liabilities restores optionality and supports valuation multiple expansion.
All standing thesis claims
Original report summary
3M's durable value comes from a diversified portfolio of patented industrial, safety and healthcare products that generate predictable revenue near $25B and mid-to-high-teens operating margins — but the stock's upside hinges on shrinking legacy.
Bull case and bear case
Bull case and bear case for 3M Co
Where the evidence on 3M Co stands: Holding on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
Core end-market demand and product breadth keep reported revenue around the mid-$20B range absent a major industrial downturn or large divestiture, so organic top-line decline would signal a structural market share loss.
3M's combination of proprietary materials, scale manufacturing and branded products allows it to sustain mid-to-high-teens operating margins in normal years; margin collapses will primarily come from one-time litigation or regulatory charges rather than competitive price erosion.
The principal driver of earnings and equity volatility is legacy litigation/reserve risk — large adverse settlements materially depress operating income, EPS and equity; conversely, materially lower future litigation cost expectations unlock equity value.
Sustained recovery in operating cash flow is required to fund dividends, buybacks and liability settlements; absent restoration to the pre-2023 cash generation regime, capital returns will be constrained.
High nominal liabilities and eroded shareholders' equity materially constrain flexibility; meaningful deleveraging or liability reduction is required before aggressive buybacks or larger M&A resumes.
Bear case: what would count against it
A prolonged global industrial downturn (weak industrial capex or safety spending) that reduces demand across multiple product lines.
Recurring regulatory fines, product bans (for example on chemical product lines) or adverse court rulings that require large operating charges again.
Adverse multi-district litigation verdicts or regulatory decisions that substantially increase settlement estimates.
Thesis-Break Engine
What has broken in 3M Co’s thesis
Each break OptimistFi flagged on 3M Co, dated — with what has historically followed the same kind of break across the market, not a forecast for 3M Co.
- Price target fell below the stockcondition set before this filing
Across all companies, this kind of break has happened 1,809 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedOther material event.
3M Co filed an SEC 8-K on 2026-09-10: Other material event. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
3M Co filed an SEC 8-K on 2026-08-19: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
3M Co filed an SEC 8-K on 2026-07-21: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A prolonged global industrial downturn (weak industrial capex or safety spending) that reduces demand across multiple product lines.
- Recurring regulatory fines, product bans (for example on chemical product lines) or adverse court rulings that require large operating charges again.
- Adverse multi-district litigation verdicts or regulatory decisions that substantially increase settlement estimates.
- Large, recurring legal cash outflows or adverse settlement schedules that materially reduce available operational cash.
- Additional large settlements or reserve increases that further erode equity.
MMM news
Loading headlines…
Financial statements
MMM income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
MMM: quick answers
- When does 3M Co (MMM) report earnings next?
- 3M Co's next results are projected for January 19, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on October 20, 2026. Earnings calendar
- What is MMM's short interest?
- As of October 30, 2026, 10.0M MMM shares were sold short, 1.93% of its shares outstanding, down 0.6% from the count before. At the stock's average daily volume that is 2.5 days to cover. FINRA publishes the count twice a month. MMM short interest history
- Have members of Congress traded MMM?
- 160 trades in MMM have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed MMM trade
- Which well-known investors own MMM?
- 2 of the 37 well-known funds tracked here reported MMM shares in their latest 13F filings. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%; ARK Investment Management (Cathie Wood), 0.0%. Fund portfolios
MMM in well-known investors’ portfolios
2 of 37 funds reported MMM shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Ray DalioBridgewater Associates | 0.01% | $2.3M | +35.6% | Q2 2026 |
| Cathie WoodARK Investment Management | 0.00% | $76K | −5.4% | Q2 2026 |
